This page shows the latest Immunomic Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Oncology is a key priority for Astellas, and along with the Ganymed buy, it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics last year, and followed it up with ... a $300m licensing deal with Immunomic Therapeutics.
Last year it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics and followed it up with a $300m licensing deal with Immunomic Therapeutics.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... Collaboration, licence. 325. Immunomic Therapeutics/ Astellas Pharma. LAMP-vax products for allergic diseases incl
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...